
Program Mission
Our mission is to prepare students for meaningful careers that provide opportunities to advocate for and implement pharmaceutical innovations to meet ever-changing healthcare challenges through relevant, rigorous, and socially informed coursework.
Program Details
Innovative, Impactful, Accessible
Leaders in the psychoactive pharmaceutical and biopharmaceutical industries – especially in the rapid-growth areas of psychedelic, entheogen, and cannabinoid research and application – are seeking employees with advanced degrees, appropriate training, and real-world experience. The Psychoactive Pharmaceutical Investigation Master’s program from the University of Wisconsin–Madison was designed from the ground up as an interdisciplinary online curriculum that prepares you to meet these needs, while giving you the background and in-demand skills needed to begin your career with an advantage or effectively transition into this exciting subfield. Graduates of this first-of-its-kind degree program will have the unique credentials to compete as outstanding applicants in industrial, not-for-profit, or academic research environments.
Importantly, the UW–Madison Master’s program in Psychoactive Pharmaceutical Investigation is not only the first accredited degree option for those students interested in pursuing the advanced study of psychedelic science, but is also dedicated to bringing this world-class educational opportunity to a truly global audience.
🙶
“Developing basic research skills… is very advantageous. This can include general laboratory experience as well as specific techniques. Project management, academic writing, and programming are extremely important across research disciplines.”
– from article “Psychedelic Research as a Career Path:
A Roundtable Discussion with Early Career Researchers in the Field”
Psychedelic Med (New Rochelle). 2024 Mar 12;2(1):44–59.
doi: 10.1089/psymed.2023.0053
Earn your degree from Experts
Program instructors are active clinicians, clinicians, researchers, and scholars with expertise in neuropharmacology, neuroscience, regulatory affairs, research ethics, biostatistics, pharmacokinetics, psychiatry, addiction medicine, counselling psychology, history of medicine, cultural studies, human ecology, and beyond. Combined, they have decades of clinical experience, dozens of active psychoactive pharmaceutical research projects, hundreds of successful graduate trainees, and thousands of original publications. Their numerous leadership roles, appointments, and consultancies support a robust network of international connections across the research and scholarly societies, not-for-profit institutes, governmental agencies, and industry partners.
How you’ll learn
- 30-credit curriculum, with flexibility to complete in 1 – 3 years
- Degree can be completed entirely online
- Face-to-face options are available for some elective courses, held on the UW–Madison campus
Skip to a Section:
In the News
- Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and Psychiatry’s, Wild Ride – Psychedelic Alpha, April 18, 2025
- UW psilocybin study gives man second chance after 10-year opioid addiction – Wisconsin Examiner, April 14, 2025
- UW psychedelic Research looks at ketamine for teens with PTSD – Wisconsin State Journal, Jan 4, 2025
- Reflecting on UW-Madison’s Fourth Annual Psychedelic Symposium – Psychedelic Bulletin (from Psychedelic Alpha), Dec 18, 2024
- MDMA’s 40-year fight for medical approval continues – Part 1: Ecstasy Therapy – Vox Media, Aug 13, 2024
- Wisconsin’s cannabis industry leafs out with new, legal products – Capital Times, Jul 10, 2024
- How delta-8 is shaping the marijuana debate in Wisconsin – Wisconsin Public Radio, Jul 17, 2024
- History of marijuana for medical use – Spectrum News – In Focus, Feb 1, 2024
- Podcast: Why UW Scientists Think Psychedelics Might Heal Trauma – City Cast Madison – Jan 3, 2024
- Psychedelic research blooms in Wisconsin – Wisconsin Examiner – Nov 20, 2023
- Podcast: The long history of psychedelic theft – Nautilis Magazine – Nov 1, 2023
- Podcast: Luminous – can psychedelics be decolonized? – WPR To the Best Of Our Knowledge – Oct 21, 2023
- How Psychedelic Drugs Can Be Used for Mental Health – NY Times, Jan 5, 2022
- UW-Madison Program to Study Psychoactive Drugs in Treatment – US News, April 10, 2021
- Psychedelics As Therapeutic Treatments To Be Focus Of New UW-Madison Master’s Program – Wisconsin Public Radio, April 4, 2021
- How Important is the ‘Psychedelic’ in Psychedelic Drug Therapies? – UW–Madison School of Pharmacy News, March 14, 2021
- Madison nonprofit furthers research on psychedelic drug and depression – Wisconsin State Journal, August 26, 2020
- Revive Therapeutics Announces Research Partnership Agreement with the UW–Madison to Evaluate Novel Formulations and Drug Delivery Technology Focused on Psilocybin-Based Pharmaceuticals – Globe Newswire, April 21, 2020